FDA grants Otsuka’s Sibeprenlimab breakthrough therapy designation in IgAN

In a significant development for the treatment of kidney disease, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sibeprenlimab, an ... Read More